Glioma wild type generally refers to glioma IDH wild type. In the 2021 edition of WHO typing, there are two types of glioblastoma IDH wild type and pediatric diffuse high-grade glioma IDH wild type. This type of glioma is highly malignant and has a poor prognosis. IDH wild-type gliomas differ from IDH mutant gliomas in that they have normal expression of the IDH gene but are often associated with other genetic abnormalities, such as TERT promoter mutations, EGFR, PTEN mutations, and so on. Clinical manifestations include increased intracranial pressure, headache, vomiting, optic papillae edema and other common signs and symptoms of increased intracranial pressure. Patients with gliomas often suffer from seizures, as well as neurological and cognitive dysfunction. Currently, clinical diagnosis often relies on CT and MRI. In addition, PET-CT, diffusion-enhanced imaging, and perfusion-compression imaging are beneficial to the diagnosis of the disease. Currently surgical treatment is the most important treatment modality, which is to remove the tumor safely in the maximum range in order to relieve the occupying effect, intracranial pressure increase, and relieve the symptoms. Treatment options such as radiotherapy and chemotherapy are also used. Common chemotherapy regimens are PCV regimen (methylbenzyl callus + vincristine + lomustine), Stupp regimen (temozolomide synergized with radiotherapy), etc. For patients diagnosed with wild-type glioma, they should immediately go to the relevant departments of regular hospitals and be treated under the guidance of specialized physicians to avoid delays.